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In intestinal epithelial cells, inactivation of APC, a key regulator of the Wnt pathway, activates b-catenin to
initiate tumorigenesis. However, other alterations may be involved in intestinal tumorigenesis. Here we found
that RUNX3, a gastric tumor suppressor, forms a ternary complex with b-catenin/TCF4 and attenuates Wnt
signaling activity. A significant fraction of human sporadic colorectal adenomas and Runx3+/ mouse intes-
tinal adenomas showed inactivation of RUNX3 without apparent b-catenin accumulation, indicating that
RUNX3 inactivation independently induces intestinal adenomas. In human colon cancers, RUNX3 is fre-
quently inactivated with concomitant b-catenin accumulation, suggesting that adenomas induced by inacti-
vation of RUNX3may progress tomalignancy. Taken together, these data demonstrate that RUNX3 functions
as a tumor suppressor by attenuating Wnt signaling.INTRODUCTION
Multiple genetic changes have been observed in colon carcino-
genesis. In familial adenomatous polyposis coli (FAP), affected
individuals carry heterozygous mutations of the APC gene,
which encodes a key regulator of the canonical Wnt pathway
that destabilizes b-catenin, one of the Wnt pathway’s nuclear ef-
fectors. Adenomas caused by biallelic inactivation of APC show
nuclear and cytoplasmic accumulation of b-catenin. In colorectal
cancers with stabilized b-catenin, the b-catenin/T cell factor 4
(TCF4) transcription factor complex is constitutively activated.
It has been widely surmised that oncogenic Wnt signaling initi-
ates colorectal carcinogenesis (Kinzler and Vogelstein, 1996).
However, studies of sporadic cases of colorectal cancer and
analyses of aberrant crypt foci (ACF)—the proposed precursors
of adenomas—have suggested that alterations other than inac-
tivation of APC or activation of b-catenin may be involved
(Jass et al., 2002). These alterations could implicate alternative
mechanisms for the activation of Wnt signaling.226 Cancer Cell 14, 226–237, September 9, 2008 ª2008 Elsevier InThe TGF-b pathway is another key pathway that influences the
growth and differentiation of gut epithelial cells and is altered in
gastrointestinal cancers (Mishra et al., 2005). Several compo-
nents of the TGF-b signaling cascade are bona fide tumor sup-
pressors that inhibit cell growth and cancer development. Inac-
tivation of one of these components, such as the TGF-b receptor
type II or Smad4, occurs frequently in gastrointestinal tumors
(Derynck et al., 2001). However, the molecular mechanisms
that link the oncogenic Wnt and the tumor-suppressive TGF-b
pathways in intestinal carcinogenesis have not been fully eluci-
dated.
RUNX3 is inactivated by gene silencing or protein mislocaliza-
tion in more than 80% of gastric cancers (Li et al., 2002; Ito et al.,
2005). More recently, inactivation of RUNX3 was reported in
a wide range of other cancer types (Blyth et al., 2005). The
RUNX3 locus at 1p36, a region that undergoes frequent allelic
loss in gastrointestinal cancers, is silenced by promoter
hypermethylation in a significant proportion of cancer-derived
cell lines and clinical specimens, suggesting that it fulfillsSIGNIFICANCE
It is known that biallelic inactivation of APC induces colon adenomas. We found that biallelic inactivation of RUNX3without
nuclear/cytoplasmic accumulation of b-catenin also induces colon adenomas. Our results suggest that APC and RUNX3
may function independently as gatekeepers in colon adenoma development. Wnt signaling is an oncogenic pathway,
whereas TGF-b signaling is a tumor suppressor pathway. The nuclear effectors of these pathways, b-catenin/TCF4 and
RUNX3, respectively, form a ternary complexwith decreasedDNA-binding ability. This ternary complex appears to integrate
growth-promoting and cytostatic signals for homeostatic balance of growth and differentiation in intestinal epithelial cells.c.
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2004; Ku et al., 2004). RUNX3 regulates target gene expression
by forming a complex with Smad molecules. We reported previ-
ously that Runx3/ gastric epithelial cells are resistant to the
growth-inhibitory and apoptosis-inducing properties of TGF-b,
suggesting that RUNX3 is a downstream effector of the TGF-b
family signaling pathway. Furthermore, TGF-b regulates nuclear
translocation of RUNX3 in gastric epithelial cells (Ito et al., 2005)
and activates the transcription of p21WAF1/Cip1 and Bim, a nega-
tive cell-cycle regulator and a proapoptotic gene, respectively, in
cooperation with RUNX3 and Smads (Chi et al., 2005; Yano et al.,
2006; reviewed in Ito, 2008).
In this study, we investigated possible roles of RUNX3 in reg-
ulating the Wnt pathway and in intestinal tumorigenesis.
RESULTS
b-Catenin/Tcf4 Activity Is Increased
in Runx3/ Mouse Intestine
Runx3 protein was detected in the epithelial cells of mouse small
and large intestines (Figures 1A and 1B). Runx3 is expressed in
all epithelial cell types in the small intestine, except in Paneth
cells, whose maturation is induced by Wnt signaling and accom-
panied by nuclear accumulation of b-catenin (Figure 1A; van Es
et al., 2005; Andreu et al., 2005). We reported previously that
Runx3/ mice on the C57BL/6 background die soon after birth
due to starvation (Li et al., 2002). However, some Runx3/ mice
on the BALB/c background survive for about 10–12 months. We
analyzed these survivors at the adult stage.
Adult and neonateRunx3/ epithelia of the small and large in-
testines show high proliferation (Figures 1D and 1E), and epithe-
lia of adult Runx3/ mice show hyperplasia (Figure 1C; see also
Figure S1A available online). Cell lines obtained from Runx3/
small and large intestinal epithelium (FID and FIL cell lines, re-
spectively) grew faster on monolayer cultures than those from
Runx3+/+ mice (Figure 1F for FID; data not shown for FIL). No tu-
mors formed in the intestines of Runx3/ mice, which die at
around 10–12 months of age. However, small intestinal adeno-
mas developed in Runx3+/ mice at about 65 weeks of age.
(Analyses of Runx3+/ intestine are described below.)
The proliferation of intestinal epithelial cells is known to be ac-
celerated by Wnt/b-catenin/Tcf4 signaling. Therefore, we exam-
ined whether Wnt signaling is activated in Runx3/ intestinal
epithelial cells. Target genes known to be positively regulated
by b-catenin/Tcf4, such as CD44, cyclin D1, c-Myc, conductin,
and EphB2 (He et al., 1998; Tetsu and McCormick, 1999; Batlle
et al., 2002; van de Wetering et al., 2002), were upregulated in the
ileum, jejunum, and colon (Figures 1G and 1I; Figure S1B), while
a gene negatively regulated by b-catenin/Tcf4, EphrinB1 (Batlle
et al., 2002), was downregulated in epithelial cells ofRunx3/ in-
testine (Figures 1G and 1I).
It has been demonstrated that the EphB/EphrinB system con-
trols the positioning of epithelial cells within the small intestinal
mucosa (Batlle et al., 2002). Enhanced b-catenin/Tcf4 activity
in Apc-deficient small intestine where the EphB/EphrinB system
is dysregulated causes displacement of epithelial cells (Sansom
et al., 2004; Andreu et al., 2005). This is clearly shown by the ran-
dom localization of Paneth cells, which are normally tightly clus-
tered at the bottom of the gland (Batlle et al., 2002). We observedCathat Paneth cells were distributed throughout the villi inRunx3/
small intestine (Figure 1H). It is noteworthy that the levels of
b-catenin and Tcf4 were not noticeably altered in intestinal epi-
thelial cells of Runx3/ mice compared to those of wild-type
(WT) mice (Figure 1I), indicating that the increase in Wnt signaling
activity in Runx3/ intestinal epithelial cells is not due to an in-
crease in the levels of these proteins. Furthermore, Runx3/
FID cells showed higher sensitivity to Wnt3a stimulation than
Runx3+/+ cells (Figure 1J). This increased b-catenin/Tcf4 activity
of Runx3/ cells after Wnt3a treatment was supported by elec-
trophoresis mobility shift assays (EMSAs), which showed in-
creased b-catenin/Tcf4 complexes bound to the TCF site after
Wnt3a treatment (Figure S3B).
Taken together, these results suggest that Runx3 regulates
Wnt signaling activity negatively.
RUNX3 Forms a Ternary Complex
with b-Catenin and TCF4
Since b-catenin and Tcf4 levels were unaffected in Runx3/ in-
testinal epithelial cells (Figure 1I), we investigated whether
RUNX3 directly inhibits the function of b-catenin/TCF4. We ex-
amined 22 well-characterized human colon cancer cell lines for
expression of RUNX3 (Figure 2A). Only 8 cell lines, HCT116,
SW480, COLO320, SW403, SW837, CCK81, SW620, and
RCM1, expressed RUNX3. We found that exogenously ex-
pressed TCF4, b-catenin, and RUNX3 coimmunoprecipitated in
HCT116 (Figure 2B) and 293T cells (data not shown) and that
they formed a ternary complex as revealed by a two-step coim-
munoprecipitation (Figure 2C). The endogenous ternary complex
was also detected in DNA-free nuclear extracts of HCT116 and
SW620 cells, which express dephosphorylated (activated) b-cat-
enin and TCF4 as well as RUNX3 in the nucleus (Figure 2D).
RUNX3 coimmunoprecipitated with TCF4 migrated slower than
RUNX3 immunoprecipitated with anti-RUNX3 or anti-b-catenin,
the reason for which is unknown. Of note, RUNX3 and TCF4 did
not interact in SW480 cells (see below). Interactions between
RUNX3 and TCF4 and between RUNX3 and b-catenin were
also observed in a cell-free system (Figure 2E). Since b-catenin
and TCF4 directly interact, our results suggest that each compo-
nent in the ternary complex interacts directly with the other two.
Mapping experiments revealed that the DNA-binding domains
of RUNX3, the Runt domain, and TCF4, the HMG box, are re-
quired for the interaction between RUNX3 and TCF4 (Figures
S2A and S2B). This result is similar to an earlier report that the in-
teraction between Runx2 and Lef1 occurs through their respec-
tive DNA-binding domains (Kahler and Westendorf, 2003).
RUNX3 was also found to interact with TCF1, TCF3, and Lef1
(Figure S2C). Interestingly, comparatively larger amounts of the
active b-catenin mutants D45 and S33Y (Morin et al., 1997) inter-
acted with RUNX3 than did wild-type b-catenin (Figure 2F).
RUNX3 Attenuates the Transactivational Potential
of b-Catenin/TCF4
To elucidate the consequences of the interaction of RUNX3 with
b-catenin/TCF4, we examined the transactivation activity of
b-catenin/TCF4. In DLD1 cells, increasing the amount of exoge-
nous RUNX3 progressively repressed the expression of a
TOPflash reporter (Figure 2G). Similarly, increasing the amount
of exogenous RUNX3 progressively repressed activity of thencer Cell 14, 226–237, September 9, 2008 ª2008 Elsevier Inc. 227
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RUNX3 Attenuates b-Catenin/TCFsFigure 1. Expression of Runx3 in Intestinal Epithelial Cells and Upregulation of b-Catenin/Tcf4 Activity in Runx3/ Intestine
(A) Immunodetection of Runx3 in wild-type (WT) and Runx3/ jejunum. Note that Runx3 expression is greatly reduced in Paneth cells (upper middle panel).
b-catenin is detected in the nuclei of these cells (arrowheads).
(B) Immunodetection of Runx3 in WT and Runx3/ proximal colon (left) and WT distal colon (right).
(C) Hematoxylin and eosin (H&E) staining of WT and Runx3/ jejunum and proximal colon of mice at 40 weeks of age.
(D) Detection of proliferating cells in WT andRunx3/ jejunum and proximal colon by BrdU incorporation (adult; 40 weeks old) and immunostaining with anti-Ki67
antibody (neonate).
(E) Number of BrdU-positive (adult) and Ki67-positive (neonate) cells per crypt in WT and Runx3/ intestine. *p < 0.001.
(F) Relative growth rates of Runx3+/+ (+/+1 and +/+2) and Runx3/ (/1 and /2) FID cell lines in monolayer culture.
(G) Immunodetection of EphrinB and EphB2 in WT and Runx3/ jejunal epithelium.
(H) Immunodetection of Paneth cells with anti-lysozyme antibody in WT andRunx3/ small intestine. Arrowheads show mispositioning of Paneth cells inRunx3/
small intestine.
(I) Western blot analysis of protein expression profiles in WT and Runx3/ intestine.
(J) Differential sensitivities of Runx3+/+ (+/+1 and +/+2) and Runx3/ (/1 and /2) FID cell lines to Wnt3a as evaluated by their relative TOP/FOP luciferase
activities (in arbitrary units). Cells were stimulated with medium containing 20% or 50% Wnt3a-conditioned medium.
Specimens were counterstained with hematoxylin in (A), (B), and (G). Error bars represent SEM in (E) and (J). Scale bars = 50 mm in (A), (B), and (G) and 100 mm in (C),
(D), (H).wild-type cyclin D1 promoter to a level comparable to that of the
promoter lacking the TCF binding site (Figure 2H; Lin et al.,
2000). The cyclin D1 reporter construct lacks RUNX binding sites
within the promoter region.
We next investigated whether the DNA-binding activity was re-
quired for RUNX3 to function as an attenuator of b-catenin/TCF4.
The RUNX mutant RUNX3(R178Q) lacks DNA-binding activity
and hence transactivation activity (Inoue et al., 2007). This
mutant interacted with b-catenin and TCF4 (Figure 2I) and atten-
uated b-catenin/TCF transactivation like wild-type RUNX3228 Cancer Cell 14, 226–237, September 9, 2008 ª2008 Elsevier Inc(Figure 2J), suggesting that RUNX3 directly inhibits the activity
of b-catenin/TCF4 independently of its DNA-binding activity.
RUNX3 Attenuates the DNA-Binding Activity
of b-Catenin/TCF4
b-catenin/TCF4 bound efficiently to consensus TCF binding
sites in the cyclin D1 and c-Myc promoters (Figure 3A, lanes 4
and 7) in DLD1 cells, as reported previously (Nateri et al.,
2005). However, when RUNX3 was stably expressed in DLD1
cells, b-catenin/TCF4 binding to either promoter was greatly.
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RUNX3 Attenuates b-Catenin/TCFsFigure 2. Detection of a b-Catenin/TCF4/RUNX3 Ternary Complex
and the Attenuation of b-Catenin/TCF4 Transcriptional Activity by
RUNX3
(A) Western blot analysis of RUNX3 expression in 22 human colorectal cancer
cell lines.
(B) Exogenously expressed b-catenin, TCF4, and RUNX3 coimmunoprecipi-
tate. HCT116 cells were transfected with Myc-TCF4 and vector (lane 1),
Myc-TCF4 and FLAG-RUNX3 (lane 2), FLAG-RUNX3 and vector (lane 3),
FLAG-RUNX3 and Myc-TCF4 (lane 4), Myc-TCF4, FLAG-RUNX3, and vector
(lane 5), or Myc-TCF4, FLAG-RUNX3, and HA-b-catenin (lane 6). Proteins
were immunoprecipitated with anti-FLAG agarose (lanes 1 and 2), anti-Myc
(lanes 3 and 4), or anti-HA (lanes 5 and 6) antibodies, and the immunoprecip-
itates were subjected to western blot analysis using anti-Myc, anti-b-catenin,
anti-HA, and anti-FLAG antibodies. * indicates detection of murine IgG (lanes 1
and 2). ** indicates that anti-b-catenin (for endogenous b-catenin; lanes 1–4)
and anti-HA (for exogenous HA-b-catenin; lanes 5 and 6) antibodies were
used.
(C) Ternary complex of exogenously expressed b-catenin/TCF4/RUNX3 de-
tected by two-step coimmunoprecipitation. 293T cells were transfected with
Myc-TCF4, S33Y b-catenin, and control vector (lane 1) or Myc-TCF4, S33YCareduced (Figure 3A, lanes 3 and 6, and Figure 3D), and c-Myc
and cyclin D1 protein levels (Figure 3E) and the expression of
a TOPflash reporter were consequently lower (Figure 3G). In con-
trast, when RUNX3 expression was inhibited by antisense
RUNX3 in HCT116 cells, the binding of b-catenin/TCF4 to these
promoters was enhanced (Figures 3B and 3D) with concomitant
upregulation of c-Myc and cyclin D1 (Figure 3E) and TOPflash
reporter expression (Figure 3G). Since the levels of TCF4 and
dephosphorylated b-catenin were unaffected in both cases
(Figure 3E), the inhibition of b-catenin/TCF4 binding to these pro-
moters depended mainly on the level of RUNX3 expression
(Figure 3C). Consistent with these observations, exogenous ex-
pression of RUNX3 downregulated the target genes of canonical
Wnt signaling AXIN2, CD44, and DKK1 in DLD1 cells, while
knockdown of RUNX3 in HCT116 cells had the opposite effect
(Figure 3F). Using three independent shRNAs to knockdown
RUNX3, we observed a consistent inhibitory effect of RUNX3
on the expression of a TOPflash reporter in HCT116, SW620,
and COLO320 cells, but not in SW480 or SW403 cells
(Figure 3H). Interestingly, RUNX3 in SW480 cells did not interact
with TCF4 (Figure 2D), whereas RUNX3 in SW403 cells was mis-
localized to the cytoplasm (see below). These results further
strengthen our conclusion that RUNX3 attenuates Wnt activity
by interacting with b-catenin/TCF4 (see Discussion).
Additionally, EMSA using a DNA probe containing a consensus
TCF site showed that RUNX3 inhibited the binding of TCF4 and
b-catenin, and FLAG-RUNX3 (lane 2). Proteins were immunoprecipitated
with anti-FLAG agarose (1st IP). Bound proteins were eluted with FLAG pep-
tide and immunoprecipitated with normal mouse IgG (lane 3) or anti-Myc anti-
body (lane 4) (2nd IP). 1st IP and 2nd IP were subjected to western blot analysis
using anti-Myc, anti-b-catenin, and anti-FLAG antibodies. * indicates nonspe-
cific band (lanes 3 and 4).
(D) Endogenous ternary complex of b-catenin/TCF4/RUNX3 in HCT116 and
SW620 cells, but not in SW480 cells. Nuclear extracts were immunoprecipi-
tated with anti-dephospho-b-catenin (activated b-catenin) antibody, anti-
TCF4 antibody, anti-RUNX3 antibody, and normal murine IgG. The immuno-
precipitates were subjected to western blot analysis using anti-dephospho-
b-catenin, anti-TCF4, and anti-RUNX3 antibodies.
(E) Interaction of in vitro-translated His-tagged RUNX3 with in vitro-translated
Myc-TCF4 and/or HA-b-catenin as revealed by pull-down assays with Ni-NTA
agarose. Western blot analysis was performed using anti-HA, anti-His, and
anti-Myc antibodies.
(F) Oncogenic b-catenins have a higher affinity for RUNX3 than wild-type
b-catenin. HCT116 cells were transfected with wild-type b-catenin, D45 b-cat-
enin, or S33Y b-catenin, together with FLAG-RUNX3 or control vector. Pro-
teins immunoprecipitated with anti-FLAG agarose were subjected to western
blot analysis using anti-b-catenin antibody.
(G) Reduction of TOPflash (0.1 mg DNA) activity by exogenous RUNX3 (0.1, 0.2,
and 0.5 mg DNA) in DLD1 cells.
(H) Exogenous RUNX3 (0.1 and 0.2 mg DNA) reduces the activity of the wild-
type cyclin D1 promoter (CyclinD1-WT; 0.1 mg), but not that of a variant pro-
moter with a mutated TCF binding site (CyclinD1-mTCF; 0.1 mg).
(I) Interaction of RUNX3(R178Q) with b-catenin/TCF4. 293T cells were trans-
fected with Myc-TCF4 and S33Y b-catenin together with control vector (lane
1), FLAG-RUNX3 (lane 2), or FLAG-RUNX3(R178Q) (lane 3). Proteins were im-
munoprecipitated with-anti-FLAG agarose. Immunoprecipitates were sub-
jected to western blot analysis using anti-Myc, anti-b-catenin, and anti-
FLAG antibodies.
(J) Reduction of TOPflash (0.1 mg DNA) activity by exogenous wild-type (WT)
RUNX3 and RUNX3(R178Q) (0.05 and 0.2 mg DNA) in DLD1 cells.
Error bars represent SEM in (G), (H), and (J).ncer Cell 14, 226–237, September 9, 2008 ª2008 Elsevier Inc. 229
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RUNX3 Attenuates b-Catenin/TCFsFigure 3. RUNX3 Attenuates the DNA-Binding Activity of b-Catenin/TCF4
(A) Exogenous RUNX3 attenuates the binding of b-catenin/TCF4 to TCF binding sites of the cyclin D1 and c-Myc promoters. DLD1 clones expressing exogenous
RUNX3 (+) or control vector () (see [E]) were subjected to ChIP analysis using antibodies against TCF4 (lanes 3 and 4), dephospho-b-catenin (lanes 6 and 7), or
normal murine IgG (lanes 5 and 8). DNA precipitates were amplified by PCR (35 or 37 cycles).
(B) Enhanced occupancy of b-catenin/TCF4 at TCF binding sites of the cyclin D1 and c-Myc promoters following RUNX3 knockdown. HCT116 clones expressing
antisense DNA against RUNX3 (AS-Cl.1, lanes 1 and 5, and AS-Cl.2, lanes 2 and 6) or control vector (control; lanes 3, 4, and 7) (see [E]) were subjected to ChIP
analysis using anti-TCF4 antibodies (lanes 5–7) or normal murine IgG (lane 4). DNA precipitates were amplified by PCR (35 or 37 cycles).
(C) Upper panel: RUNX3 displaces TCF4 from TCF binding sites of the cyclin D1 and c-Myc promoters in a dose-dependent manner. A DLD1 stable transfectant in
the lower panel was subjected to ChIP assay with the indicated antibodies and number of PCR cycles. Lower panel: western blot analysis of RUNX3 induction in
DLD1 stably transfected with inducible RUNX3 following stimulation with 20 mM ponasterone A (Pon A).
(D) Quantification by real-time PCR of ChIP assay for TCF4 and b-catenin occupancy at TCF consensus sites of the cyclin D1 (white bars) and c-Myc (gray bars)
promoters. Relative occupancy in the RUNX3-expressing DLD1 clone was compared to that in the control clone (see [E]). TCF4 binding in HCT116 clones in which
RUNX3 was knocked down (AS-Cl.1 and AS-Cl.2) was compared to that in the control clone (see [E]). Relative extent of PCR amplification of ChIP using negative
control primer sets (designed for the cyclin D1 and c-Myc promoters) that do not flank any TCF consensus sites was less than 0.0001 in all trials.
(E) Protein expression profile in DLD1 clones transfected with vector (control) or FLAG-RUNX3 (RUNX3) and in HCT116 clones expressing control vector (control)
or antisense RUNX3 DNA (AS-Cl.1 and AS-Cl.2), as detected by western blot analysis.
(F) Left panel: real-time PCR quantification of AXIN2, CD44, and DKK1 mRNA in DLD1 cells with inducible RUNX3 expression. The amount of mRNA 24 hr after
induction by Pon A was normalized against noninduced samples. Right panel: the amount of mRNA of the same set of genes in HCT116 cells in which RUNX3 was
knocked down (average of AS-Cl.1 and AS-Cl.2; see [E]) was normalized to the control clone.
(G) TOPflash versus FOPflash activity (in arbitrary units) for control DLD1 cells (white bars) and DLD1 cells expressing RUNX3 (black bars; see [E]), and for control
HCT116 cells (black bars) and HCT116 cells in which RUNX3 was knocked down (white bars; see [E]).
(H) Differential effects of RUNX3 knockdown in HCT116, SW620, COLO320, SW480, and SW403 cells. Upper panel: western blot analysis showing RUNX3 ex-
pression in cells treated with three independent RUNX3 shRNAs (sh1–3) and control shRNA. Lower panel: TOPflash/FOPflash activity in cells after RUNX3 knock-
down was normalized to that of the controls.
Error bars represent SEM in (D), (F), and (G).b-catenin/TCF4 to the TCF binding site in a dose-dependent
manner (Figure S3A). Conversely, RUNX3 lost affinity for the
RUNX site when bound to b-catenin/TCF4 (Figure S3C). These230 Cancer Cell 14, 226–237, September 9, 2008 ª2008 Elsevier Incresults suggest that RUNX3 and TCF4 mutually inhibit their re-
spective DNA-binding activities through interactions involving
their DNA-binding domains..
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Are Induced in Intestine of Runx3+/ and Runx3+/
ApcMin/+ Mice, Respectively
Since Wnt signaling is a well-known oncogenic pathway and
RUNX3 is a nuclear effector of the well-established TGF-b tumor
suppressor pathway, an intriguing possibility is that oncogenicity
in intestinal epithelial cells reflects the relative activities of these
two antagonistic pathways. The gastrointestinal tract epithelium
of Runx3+/ mice was indistinguishable from that of Runx3+/+
mice over a 1 year observation period. However, at around 65
weeks of age, small adenomas developed in the small intestine
of Runx3+/ mice at a frequency comparable to that of ApcMin/+
mice on the same BALB/c background (54% of Runx3+/ mice
and 64% of ApcMin/+ mice at 65 weeks; Figures 4A and 4B). All
intestinal tumors obtained from Runx3+/ (n = 54) and ApcMin/+
(n = 22) mice were adenomatous polyps. Adenomatous polyps
were also found in small intestine of Runx3+/ mice on other ge-
netic backgrounds, such as C3H/HeJ, at 65 weeks of age (55%
of Runx3+/ mice [6 of 11] developed 2.2 ± 0.9 tumors).
Loss of heterozygosity (LOH) of Apc, indicating biallelic inacti-
vation of the gene, occurs frequently in adenomatous polyps of
ApcMin/+ mice (Polakis, 2000). Similarly, we found LOH of Apc
in adenomatous polyps of ApcMin/+ mice in this study
(Figure S4B). In the case of adenomatous polyps of Runx3+/
mice, downregulation of Runx3 expression was observed (Fig-
ures 5A and 5C), but LOH of Runx3 was not detected
(Figure S4A). Instead, we detected CpG island methylation of
the Runx3 promoter (Guo et al., 2002), suggesting that Runx3
promoter methylation is one of the causes of Runx3 repression
in adenoma cells (Figure S4C).
Adenomatous polyps found in both Runx3+/ and ApcMin/+
small intestines displayed upregulation of cyclin D1 and c-Myc
(Figures 5A, 5C, and 5D) and downregulation of p21 (Figures
5C and 5D), which is consistent with an earlier report that p21
can be repressed by b-catenin/TCF4 (van de Wetering et al.,
2002). In both types of tumors, binding of b-catenin/Tcfs to the
Tcf consensus sites in the cyclin D1 and c-Myc promoters was
enhanced despite the fact that obvious nuclear accumulation
of b-catenin was observed only in ApcMin/+ mice (Figures 5E–
5G). These results indicate that the nuclear accumulation of on-
cogenic b-catenin in ApcMin/+ mice and the downregulation of
Runx3 in Runx3+/ mice induce common phenotypes in our ex-
perimental system. To confirm that the tumorigenicity of cells de-
ficient in Runx3 activity is dependent on the activity of b-catenin/
Tcf4, we used Runx3/ FID and FIL cells. Only Runx3/ FID
and FIL cells, but notRunx3+/+ cells, formed tumors in inoculated
mice (Figure S9C). Runx3/ FID and FIL cells stably expressing
a dominant-negative form of TCF4 (van de Wetering et al., 2002)
showed that the tumorigenicity of Runx3/ FID and FIL cells
was indeed attenuated by inhibition of b-catenin/Tcf4
(Figure S9D).
Since RUNX3 and b-catenin/TCF4 antagonize each other, in-
activation of Runx3 in ApcMin/+ mice should enhance intestinal
carcinogenesis. In Runx3+/ and ApcMin/+ mice, adenomatous
polyps (0.2 mm or larger in diameter) were induced in the small
intestine, but not in the large intestine. In Runx3+/ApcMin/+
mice, on the other hand, invasive adenocarcinomas (generally
larger than 5 mm in diameter; Figures 4A and 4D) and adenoma-
tous polyps were seen in the small and large intestines,CaFigure 4. Adenomatous Polyps in Small Intestine of Runx3+/ and
ApcMin/+ BALB/c Mice and Progression to Adenocarcinoma in
Runx3+/ApcMin/+ Mice
(A) H&E staining of tumors in small intestine of Runx3+/, ApcMin/+, and
Runx3+/ApcMin/+ mice at 65 weeks of age. Runx3+/ApcMin/+ mice developed
adenocarcinomas. Boxed regions are enlarged at right. Scale bars = 1 mm
(left) and 100 mm (right).
(B) Frequency of tumor formation in small and large intestines of mice of the
indicated genotypes at 65 weeks of age. Tumors > 0.2 mm in diameter
were counted.
(C) Number of tumors in small intestines of individual mice of the indicated ge-
notypes at 65 weeks of age. Error bars represent SEM. *1p < 0.01; *2p < 0.05.
(D) Size distribution of polyps in small intestines of mice of the indicated geno-
types at 65 weeks of age. Size classes indicate tumor diameter.ncer Cell 14, 226–237, September 9, 2008 ª2008 Elsevier Inc. 231
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RUNX3 Attenuates b-Catenin/TCFsFigure 5. Adenomatous Polyps in Small Intestine ofRunx3+/BALB/cMice Displaying Downregulated Runx3 and Upregulated Cyclin D1 and
c-Myc
(A) Immunodetection of Runx3, b-catenin, cyclin D1, and c-Myc in adenomatous polyps formed in the small intestine of Runx3+/ and ApcMin/+ mice at 65 weeks
of age. Dashed lines indicate the border between normal and adenomatous cells (marked ‘‘A’’).
(B) Very small adenomas formed in the jejunum of Runx3+/ApcMin/+ mice were analyzed. When Runx3 was downregulated, b-catenin was not activated (upper
panels). In contrast, when b-catenin was activated, Runx3 was not downregulated (lower panels).
Specimens were counterstained with hematoxylin in (A) and (B). Scale bars = 100 mm in (A) and (B).
(C and D) Quantification by real-time PCR of Runx3, cyclin D1, c-Myc, and p21 mRNA in individual polyps (T1–3) in Runx3+/ (C) and ApcMin/+ (D) small intestines,
normalized to the values of adjacent normal epithelium.
(E) Enhanced binding of b-catenin/Tcfs to the Tcf consensus site of the cyclin D1 promoter, as revealed by ChIP assay in polyps (T1 and T2) and adjacent normal
tissues (N1 and N2) of Runx3+/ and ApcMin/+ small intestines. T1 and T2 represent two pools of 3–4 polyps each from 1–2 mice with adenomas used for the ChIP
assay. DNA fragments precipitated by anti-b-catenin antibody or control IgG were amplified by PCR (33 cycles). The Gapdh promoter region was amplified as
a negative control.
(F and G) Real-time PCR quantification of ChIP to measure bound b-catenin/Tcfs at Tcf consensus sites of the cyclin D1 (F) and c-Myc (G) promoters, normalized
to the inputs.respectively (33.3% of 21 mice, 1–2 tumors per mouse;
Figure 4B), at 65 weeks of age. Frequency of tumor formation,
number of tumors per mouse, and tumor size were all increased
in the small intestine of Runx3+/ApcMin/+ mice (Figures 4B–4D).
An examination of the very small adenomas from Runx3+/
ApcMin/+ mice showed either nuclear accumulation of b-catenin
or loss of Runx3 expression, but not both (Figure 5B). This result
is consistent with the hypothesis that the adenomas were
induced by biallelic inactivation of either Apc or Runx3. This
observation explains why the number of tumors in Runx3+/
ApcMin/+ small intestine was nearly equal to the sum of the
tumors in ApcMin/+ and Runx3+/ mice (Figure 4C). When the
large adenomas or adenocarcinomas of the Runx3+/ApcMin/+
mice were examined, b-catenin accumulation was observed in
most cases, suggesting that alterations in both genes result in
stronger activation of the Wnt pathway.232 Cancer Cell 14, 226–237, September 9, 2008 ª2008 Elsevier InThe extent of intestinal tumorigenicity conferred by the
Apc+/ genotype varies in different mouse strains, with a higher
incidence in C57BL/6 than in others (Shoemaker et al., 1997).
We examined the effect of the C57BL/6 genetic background
on the tumorigenicity of Runx3+/ and ApcMin/+ using the F1
mice from the BALB/c 3 C57BL/6 cross. Although the tumori-
genicity of ApcMin/+ mice was strongly enhanced as expected,
no tumors were observed in Runx3+/ mice within the 25 week
observation period after birth (Figure S5A), and the numbers of
tumors in the intestines of ApcMin/+ and Runx3+/ApcMin/+ mice
were comparable at about 25 weeks of age (Figure S5B).
Nevertheless, Runx3+/ status significantly promoted ApcMin/+
tumorigenicity, as the size of small intestinal tumors and the
frequency of large intestinal tumors were enhanced in
Runx3+/ApcMin/+ mice on the BALB/c 3 C57BL/6 background
(Figures S5A, S5C, and S5D).c.
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RUNX3 Attenuates b-Catenin/TCFsRUNX3 Is Frequently Downregulated in Human
Colon Adenomatous Polyps without Apparent
Accumulation of b-Catenin
We next examined RUNX3 expression and b-catenin accumula-
tion in sporadic human colon adenomatous polyps. Ten of thirty-
five cases (29%) tested showed reduced RUNX3 without appar-
ent nuclear/cytoplasmic accumulation of b-catenin (‘‘type B’’;
Figure 6B and Figure S6B), while 15 of 35 cases (43%) showed
accumulation of b-catenin without inactivation of RUNX3
(‘‘type A’’; Figure 6A and Figure S6A). The remaining cases
showed membranous b-catenin without inactivation of RUNX3
(‘‘type C’’; Figure 6C and Figure S6C). In both A and B types of
adenomas, upregulation of cyclin D1 and c-Myc was observed
consistently (Figures 6D and 6E). Cyclin D1 and c-Myc were up-
regulated in 100% (13/13) and 92% (12/13), respectively, of type
A polyps and 80% (8/10) and 100% (10/10), respectively, of type
B polyps. Another target gene of canonical Wnt signaling, CD44,
was also upregulated in 100% (10/10) of both A and B types (Fig-
ures S7A and S7B). In type C polyps, on the other hand, cyclin
D1, c-Myc, and CD44 were upregulated in 67% (6/9), 67%
(6/9), and 86% (6/7) of cases, respectively (data not shown).
Therefore, Wnt target genes are upregulated in two-thirds or
more of type C cases, suggesting that there might be another
activation mechanism of Wnt signaling.
In agreement with the mouse cases, methylation of theRUNX3
promoter region was detected in all cases that showed downre-
gulation of RUNX3 (Figures 6F and 6G; Table S1). We frequently
observed the unmethylated allele in addition to the methylated
allele (Figure 6F). This is likely because small tumors that we an-
alyzed were inadvertently contaminated with normal surround-
ing tissue wherein the RUNX3 promoter was unmethylated.
Methylation was also detected in some adenomas that ex-
pressed RUNX3 (Table S1). This is probably due to partial meth-
ylation of the promoter region. It is likely that RUNX3 is bialleli-
cally inactivated in human colon adenomatous polyps in which
RUNX3 expression is lost without b-catenin accumulation (type
B), since monoallelic inactivation of Runx3 per se does not elim-
inate the expression of Runx3 in mice.
RUNX3 Is Frequently Inactivated in Human Colorectal
Cancers Showing Concomitant Accumulation
of b-Catenin
As colon adenomas do not always progress to carcinomas (Kin-
zler and Vogelstein, 1996), we examined whether RUNX3 is inac-
tivated in colon carcinomas. Consistent with earlier reports by
others (Kinzler and Vogelstein, 1996; Bodmer, 2006), nuclear/cy-
toplasmic accumulation of b-catenin was observed in 45 of 48
specimens tested (94%) (Figures 7A–7C; Table S2). On the other
Figure 6. Downregulation of RUNX3 Ex-
pression without Nuclear Accumulation of
b-Catenin in Human Adenomatous Polyps
(A–C) Three patterns of b-catenin and RUNX3 ex-
pression in 35 human cases: type A, nuclear b-cat-
enin with RUNX3 in nuclei (A); type B, membra-
nous b-catenin without RUNX3 expression (B);
and type C, membranous b-catenin with RUNX3
expression (C). Images in (A), (B), and (C) show
cases T4, T6, and T9 in (F), respectively. Enlarge-
ment of part of (A)–(C) is shown in Figure S6.
(D and E) Upregulation of cyclin D1 and c-Myc in
adenomas of type A (D) and type B (E).
Four slides each of adenomas and adjacent nor-
mal epithelium shown in (A) and (D) (type A) and
in (B) and (E) (type B) are all serial sections. Re-
gions indicated by boxes in larger images are
magnified in the insets. Specimens were counter-
stained with hematoxylin. Scale bars = 100 mm in
larger images and 20 mm in insets.
(F) Methylation-specific PCR (MSP) analysis of the
RUNX3 promoter in normal human colon epithe-
lium and DLD1 and HCT116 cells. Data are repre-
sentative of 15 (T1–15) of a total of 35 human ade-
nomatous polyps (see Table S1).
(G) Methylation status of the CpG dinucleotide be-
tween 70 and 21 relative to the translation initi-
ation site of the RUNX3 exon 1 region. The nucle-
otide sequence (sense strand) of the MSP
products from RUNX3-positive and -negative tu-
mors and DLD1 and HCT116 cells are shown. A
red C indicates resistance to bisulfite treatment
due to methylation. Unmethylated C (indicated in
blue) was converted to T by bisulfite treatment.
An asterisk above a T indicates an unmethylated
C residue in RUNX3-negative tumors.Cancer Cell 14, 226–237, September 9, 2008 ª2008 Elsevier Inc. 233
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RUNX3 Attenuates b-Catenin/TCFsFigure 7. RUNX3 Inactivation by Gene Si-
lencing and Protein Mislocalization with
Concomitant Accumulation of b-Catenin in
Human Colorectal Cancers
(A–C) Differential staining patterns of RUNX3 in hu-
man colorectal cancers. Positive (A), negative (B),
and cytoplasmic positive (C) are summarized as
‘‘P,’’ ‘‘N,’’ and ‘‘C,’’ respectively, in Table S2.
Specimens were counterstained with hematoxy-
lin.
(D) Differential staining patterns of RUNX3 in hu-
man colorectal cancer cell lines: positive
(HCT116 and SW480), negative (DLD1 and RKO),
and cytoplasmic positive (SW403 and CCK81).
Scale bars = 100 mm in (A)–(C) and 50 mm in (D).hand, RUNX3 was found to be reduced in 14 of 48 cases (29%)
(Figure 7B; ‘‘N’’ in Table S2) and localized in cytoplasm, an alter-
native mechanism of RUNX3 inactivation (Ito et al., 2005), in 7 of
48 cases (15%) (Figure 7C; ‘‘C’’ in Table S2). RUNX3 was there-
fore inactive in at least 44% of colon cancers, most of which
showed nuclear/cytoplasmic accumulation of b-catenin (Table
S2). This was in contrast to human colon adenomas, none of
which showed simultaneous nuclear/cytoplasmic accumulation
of b-catenin and RUNX3 inactivation (Figure 6). RUNX3 inactiva-
tion is also prevalent in human colorectal cancer cell lines.
RUNX3 was undetectable in 14 of 22 human colorectal cancer
cell lines (Figure 2A), was excluded from the nucleus in SW403
and CCK81 cell lines (Figure 7D), and did not interact with
TCF4 in the SW480 cell line. The growth-inhibitory and tumor-
suppressive effects of RUNX3 in the human colorectal cancer
cell lines DLD1 (RUNX3-negative) and HCT116 (RUNX3-posi-
tive), both of which are b-catenin-activated cell lines, were con-
firmed by the exogenous expression of RUNX3 and knockdown
of RUNX3, respectively (Figures S9A and S9B).
It was previously reported that Runx3 was not expressed in in-
testinal epithelial cells and that the intestinal hyperplasia ob-
served in Runx3/ mice was due to inflammation caused by
loss of Runx3 function in leukocytic populations (Brenner et al.,
2004). However, we observed only a few small foci of inflamma-
tion in colon epithelium of our Runx3/ mice (Figure S1A). In-
flammation is therefore unlikely to cause hyperplastic changes
in Runx3/ intestine. We used two approaches to further con-
firm that the loss of Runx3 function in intestinal epithelial cells
is responsible for their tumorigenic potential. In the first ap-
proach, we generated mice whose leukocytes but not epithelial
cells were Runx3/ by transplanting bone marrow cells of
Runx3/ mice into irradiated wild-type mice. Histological exam-
ination of the small and large intestines of these mice 1 year after
transplantation revealed neither hyperplasia nor dysplasia (Fig-
ures S8A–S8E). In the second approach, we compared the tu-
morigenicity of Runx3+/+ and Runx3/ FID and FIL cells in
nude mice. As mentioned earlier and as shown in Figure S9C,
only Runx3/ cells formed tumors. These results indicate that
the tumorigenicity of intestinal epithelial cells of Runx3/ mice
is epithelial cell autonomous. Our results do not, however, ex-234 Cancer Cell 14, 226–237, September 9, 2008 ª2008 Elsevier Incclude the possibility that leukocytes or other mesenchymal cells
may affect the growth of epithelial cells when the intestinal epi-
thelium is encompassed by these cells, as reported for
Smad4-deficient mice (Kim et al., 2006; Pan et al., 2007).
DISCUSSION
Our results show that inactivation of either RUNX3 or APC can
induce intestinal adenomas in humans and mice. However, inac-
tivation of both RUNX3 and APC appears to provide a more
favorable condition for the progression of these adenomas to
adenocarcinomas.
The results presented here suggest that RUNX3 modulates the
strength of activated Wnt signaling, either physiologically by Wnt
ligands or pathologically by APC inactivation or b-catenin activa-
tion, through interaction with the b-catenin/TCF4 complex. In the
absence of Wnt ligand stimulation, RUNX3 inactivation will not
affect TCF4 and b-catenin protein levels or result in aberrant
Wnt pathway activity. Without RUNX3, the b-catenin/TCF4 tran-
scriptional activity resulting from normal Wnt ligand activation is
enhanced or prolonged, or both, owing to the absence of
RUNX3-mediated repression. Even when the Wnt pathway is ab-
errantly activated due to APC inactivation or b-catenin activa-
tion, the signal output may still be restrained by RUNX3. Con-
comitant inactivation of APC, or activation of b-catenin, and
inactivation of RUNX3 would result in ligand-independent and
unconstrained Wnt pathway signaling that favors the progres-
sion of intestinal tumors.
Of the five RUNX3-positive human colon cancer cell lines
tested, knockdown of RUNX3 in the SW480 and SW403 cell lines
did not result in a significant increase in b-catenin/TCF4 tran-
scriptional activity, which can be attributed to the lack of interac-
tion between RUNX3 and TCF4 in SW480 cells and protein mis-
localization in SW403 cells (Figure 3H). This result emphasizes
the importance of the interaction between RUNX3 and TCF4
for attenuation of Wnt signaling by RUNX3. Preliminary results
suggest that RUNX3-TCF4 interaction is regulated by a signaling
pathway that appears to be defective in SW480 cells. Therefore,
it is possible that RUNX3 may be inactive in certain colon can-
cers even when it is expressed and properly localized in nuclei..
Cancer Cell
RUNX3 Attenuates b-Catenin/TCFsWhen adenomatous polyps were induced in Runx3+/ intes-
tine, the remaining intact Runx3 allele was silenced in the major-
ity of the polyps as judged by Runx3 promoter methylation. This
suggests that inactivation of Runx3 occurs at an early stage of
carcinogenesis. CpG island methylator phenotype (CIMP) has
been proposed as a mechanism for sporadic colorectal cancer
(Toyota et al., 1999). As many as 35%–40% of colorectal cancers
have been classified as CIMP (Goel et al., 2007), and RUNX3 is
one of five markers used to classify CIMP+ tumors (Weisen-
berger et al., 2006).
Transgenic ApcMin/+ mice overexpressing the DNA methyl-
transferase Dnmt3b show increased tumorigenesis (Linhart
et al., 2007). In the tumors of these mice, the tumor suppressor
genes Sfrp2, Sfrp4, and Sfrp5 are methylated and silenced,
whereas Mlh1, Mgmt, Cdkn2b, Apc, Rb1, Vhlh, and Brca1,
genes often methylated in cancer cells, are not. Given that Lin-
hart et al. also noted reduced Runx3 expression in the tumors
of these mice, our conclusion that Runx3 is a downstream atten-
uator of Wnt signaling cascade seems plausible. Whether Runx3
is a target of Dnmt3b during the early stages of carcinogenesis
remains to be determined.
Somewhat surprisingly, Runx3/ mice did not develop epi-
thelial tumors, unlike Runx3+/ mice. As homozygous mutant
mice typically die at around 10 months of age, it may be that
they die before tumors can form. However, this might not be
the only explanation. In studies of acute myeloid leukemia, it
has been shown that homozygous inactivation of the transcrip-
tion factors PU.1, C/EBPa, or GATA-1 hardly induces leukemia,
whereas a strong association is observed between leukemogen-
esis and hypomorphic alleles of these transcription factors, sug-
gesting that a threshold level of gene expression is required for
carcinogenesis (reviewed by Rosenbauer et al., 2005). This
might be the case as well in Runx3+/ mice.
Gut development and intestinal stem cell maintenance and dif-
ferentiation are regulated by interactions between key signaling
pathways. Since b-catenin and TCF4 are downstream effectors
of the canonical Wnt signaling pathway and RUNX3 is a nuclear
effector of the TGF-b superfamily, our results suggest that prolif-
eration signals transmitted by the Wnt pathway and antiprolifera-
tion signals transmitted by the TGF-b family pathway culminate in
the ternary complex formed by b-catenin/TCF4 and RUNX3. The
ternary complex would function to harmoniously coregulate gut
development and maintain the normal proliferative state of the
gut epithelium. In this study, we showed that a DNA-binding-neg-
ative mutant of RUNX3 can attenuate b-catenin/TCF4 activity, in-
dicating that RUNX3 can act independently of its transcription
factor activity. Judging from the data presented here, its activity
as an attenuator of the Wnt signaling pathway would have a pro-
found role in gut development, homeostasis, and cancer. The ob-
servations made here provide insight into the interaction between
the Wnt and TGF-b superfamily pathways in intestinal tumorigen-
esis. How this interaction is further regulated by interactions with
other signaling pathways is currently under investigation.
EXPERIMENTAL PROCEDURES
Cell Lines, Mouse Lines, and RUNX3 shRNAs
Colorectal cancer cells were maintained in DMEM supplemented with 10%
fetal bovine serum. Transfections with pcDNA3, pcDNA-FLAG-RUNX3, orCpEF-BOS-neo-RUNX3-AS were performed as described previously (Ito
et al., 2005). Stable transfectants were selected using 0.5 mg/ml G418
(GIBCO). An ecdysone-inducible FLAG-RUNX3 clone of DLD1 was prepared
as described previously (Yamamura et al., 2006). shRNAs targeting RUNX3
(sh1, 50-GCCCAGAGAAGATGAGTCTAT-30; sh2, 50-AAGCAGCTATGAATC
CATTGT-30; sh3, 50-TCAGTAGTGGGTACCAATCTT-30) and control shRNA
were obtained from SuperArray Bioscience. pGeneClip-hMGFP (Promega)
was used as the vector for transfection. Sorted cells showing GFP expression
were subjected to western blot analysis and transfected with the reporter plas-
mids TOPflash and FOPflash (Upstate).
Immunocytochemistry to detect RUNX3 in colorectal cancer cell lines was
performed using anti-RUNX3 antibody (MBL R3-6E9; Ito et al., 2005).
Mouse small and large intestinal epithelial cell lines FID and FIL, respec-
tively, were established from isolated intestinal epithelium of 16.5 dpc
Runx3+/+p53/ and Runx3/p53/ fetuses on the C57BL/6 background
and maintained as described previously for similarly obtained mouse gastric
epithelial cell lines (Li et al., 2002).
To generate Runx3-deficient and ApcMin/+ mice on the BALB/c background,
male Runx3+/ mice on the C57BL/6 background (Li et al., 2002) and
C57BL/6Min/+ mice (The Jackson Laboratory) were backcrossed with wild-
type BALB/c female mice for at least six generations. Animal studies were ap-
proved by the Institutional Animal Care and Use Committee of the National
University of Singapore (protocol numbers 752/05 and 857/05).
Histological Analysis
Tissues were fixed with 10% formalin (for human tissues) or 4% paraformalde-
hyde (for mouse tissues), embedded in paraffin, and sectioned (5 mm). Anti-
RUNX3 (MBL R3-1E10 for mouse; Yano et al., 2006; MBL R3-6E9 for human;
Ito et al., 2005), anti-Ki67 (DAKO M7249), anti-c-Myc (Santa Cruz sc-764 for
mouse; Upstate 06-340 for human), anti-EphrinB1 (Santa Cruz sc-910), anti-
EphB2 (R&D Systems AF467), anti-lysozyme (DAKO A0099), anti-cyclin D1
(Zymed 13-4500 for mouse; Novocastra NCL-CYCLIN D1-GM for human),
and anti-b-catenin (Santa Cruz sc-7199) antibodies were used on rehydrated
sections pretreated with Target Retrieval Solution (DAKO). An EnVision+ sys-
tem (HRP/DAB) (DAKO) was used for visualization. BrdU incorporation and
cellular proliferation were detected with a BrdU Labeling and Detection Kit II
(Roche).
Human Polyps and Cancers
All polyps tested were adenomas resected during colonoscopic examination
in the context of regular screening and were made up of approximately similar
proportions of left- and right-sided adenomas. The carcinomas were surgically
resected. None of the patients with adenomas or carcinomas had a clinical
presentation (including family history) reminiscent of inherited carcinoma or
histological features suggesting an inherited pattern. Indeed, from both clinical
and pathological viewpoints, the adenomas and carcinomas were sporadic in
nature. Furthermore, the patients had no other predisposing factors and, in
particular, no inflammatory bowel disease. The human tissue samples in this
study were analyzed with prior approval from the institutional ethics committee
of the National University of Singapore (NUS-IRB reference number 06-178).
Western Blot Analysis and Immunoprecipitation
Lysates prepared from colorectal cancer cell lines and mouse intestinal tissues
containing 30 mg of proteins were analyzed by western blot using anti-RUNX3
(MBL R3-5G4; Ito et al., 2005), anti-dephosphorylated b-catenin (Alexis ALX-
804-260 for human; Upstate 05-665 for mouse), anti-TCF4 (Upstate 05-511),
anti-CD44 (Endogen MA-4405), anti-c-Myc (Santa Cruz sc-40 for human;
Santa Cruz sc-764 for mouse), anti-cyclin D1 (BD Biosciences 556470), anti-
conductin (Santa Cruz sc-8570), anti-EphrinB1 (R&D Systems AF473), anti-
EphB2 (R&D Systems AF467), and anti-b-actin (Sigma A5441) antibodies.
Whole-cell extracts of HCT116 or 293T cells expressing 63Myc-TCF4,
FLAG-RUNX3, FLAG-RUNX3(R178Q) (Inoue et al., 2007), HA-b-catenin, b-cat-
enin (WT), b-catenin (D45; Morin et al., 1997), or b-catenin (S33Y; Morin et al.,
1997) were immunoprecipitated with anti-Myc (Santa Cruz sc-789), anti-HA
(Santa Cruz sc-805), and anti-b-catenin (BD Biosciences 610153) antibodies
or anti-FLAG M2 agarose (Sigma A2220), followed by western blot analysis us-
ing anti-Myc (Santa Cruz sc-40), anti-HA (Santa Cruz sc-7392), anti-b-catenin
(BD Biosciences 610153), or anti-FLAG (Sigma F7429) antibodies. Forancer Cell 14, 226–237, September 9, 2008 ª2008 Elsevier Inc. 235
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RUNX3 Attenuates b-Catenin/TCFstwo-step coimmunoprecipitation, 33FLAG peptide (Sigma F4799) was used
to elute proteins from anti-FLAG M2 agarose.
To detect endogenous protein interactions, nuclear extracts were prepared
using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce) and
treated with DNase I (Promega). Immunoprecipitation was performed using
anti-RUNX3 (MBL R3-5G4), anti-TCF4 (Upstate 05-511), or anti-dephosphory-
lated b-catenin (Alexis ALX-804-260) antibodies or mouse normal IgG, fol-
lowed by western blot analysis.
HA-b-catenin, 63Myc-TCF4, and 63His-RUNX3 were translated in vitro us-
ing the TNT T7 Quick Coupled Transcription/Translation System (Promega
L1170). Proteins pulled down by Ni-NTA agarose (QIAGEN 30210) were re-
vealed by western blot analysis using anti-HA (Santa Cruz sc-7392), anti-
Myc (Santa Cruz sc-40), and anti-His (Clontech 631212) antibodies.
Reporter Assay
The mutant cyclin D1 promoter construct (CyclinD1-mTCF) was made by mu-
tating the TCF consensus sequence located near the nucleotide 80 (from
CTTTGATC to CTTTGGCC) in D1D-944pXP2 (CyclinD1-WT; Herber et al.,
1994) using a QuikChange XL Site-Directed Mutagenesis Kit (Stratagene).
DLD1 cells were transfected with reporter plasmids; TOP/FOPflash (Upstate),
CyclinD1-WT, or CyclinD1-mTCF along with pRL-TK (Promega) and
effector plasmids; pcDNA3, pcDNA-FLAG-RUNX3, or pcDNA-FLAG-
RUNX3(R178Q) using FuGENE 6 (Roche). Luciferase activity was measured us-
ing the Dual-Luciferase Reporter Assay System (Promega) and normalized to
luciferase activity expressed by pRL-TK. To examine the b-catenin/Tcf-depen-
dent reporter activities in response to Wnt3a stimulation, FID cells were trans-
fected with TOP/FOPflash and treated with conditioned media collected from
Wnt3a-expressing or parental L cell cultures (Shibamoto et al., 1998) for 24 hr.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using a Chromatin Im-
munoprecipitation Assay Kit (Upstate) and anti-TCF4 (Santa Cruz sc-13027)
and anti-dephosphorylated b-catenin (Alexis ALX-804-260) antibodies or
mouse normal IgG. Primers used to amplify DNA fragments containing the
TCF consensus site were 50-AGGCGCGGCGGCTCAGGGATG-30 and 50-ACT
CTGCTGCTCGCTGCTACT-30 for the human cyclin D1 promoter (Nateri et al.,
2005), 50-TTGCTGGGTTATTTTAATCAT-30 and 50-ACTGTTTGACAAACCGCA
TCC-30 for the human c-Myc promoter (Nateri et al., 2005), 50-CCTCCCCCT
TTTCTCTGCCC-30 and 50-CCTCTGGAGGCTGCAGGACTTTGC-30 for the
murine cyclin D1 promoter, and 50-AATGCACAGCGTAGTATTCAGG-30 and
50-AAACCGTTAACCCCTTCCTCC-30 for the murine c-Myc promoter. Primers
used as negative controls were 50-CGTCTTCACCACCATGGAGA-30 and
50-CGGCCATCACGCGACAGTTT-30 for the human GAPDH gene (Nateri
et al., 2005) and 50-GGGGTTGCTGTGTCACTACCG-30 and 50-CAGAGACCT
GAATGCTGCTTCC-30 for the murine Gapdh gene.
Quantitative PCR for ChIP was performed using a SYBR Green PCR Kit
(QIAGEN) and a 7500 Fast Real-Time PCR System (Applied Biosystems). The
following primers were used for quantitative PCR amplification of regions of
human gene promoters containing the TCF consensus site and no TCF site, re-
spectively: 50-CCCTCCCGCTCCCATTC-30/50-TACAGGGGAGTTTTGTTGAA
GTTG-30 and 50-GCAGTCGCTGAGATTCTTTGG-30/50-AGAATGGGCGCATTT
CCA-30 for the cyclin D1promoter, and 50-CCCGTCTAGCACCTTTGATTTC-30/
50-TGTTGCAAACCGGCGC-30 and 50-CGGCAGCCCGAGACTGT-30/50-TCAG
AAGAGACAAATCCCCTTTG-30 for the c-Myc promoter.
Quantitative RT-PCR
Quantitative RT-PCR was performed using an RNeasy Kit (QIAGEN), Omni-
script RT Kit (QIAGEN), 7500 Fast Real-Time PCR System (Applied Biosys-
tems), and TaqMan Gene Expression Assays (Applied Biosystems;
Hs00610344_m1 for human AXIN2; Hs00153304_m1 for human CD44;
Hs00183740_m1 for humanDKK1; Hs99999903_m1 for human b-actin for nor-
malization; Mm00490666_m1 for murine Runx3; Mm00432359_m1 for murine
cyclin D1; Mm00487803_m1 for murine c-Myc; Mm00432448_m1 for murine
p21; Mm99999915_g1 for murine Gapdh for normalization).
Methylation-Specific PCR and Bisulfite Sequencing
Genomic DNA extracted by proteinase K digestion from rehydrated sections of
human tissues or DLD1 and HCT116 cells was treated with sodium bisulfite236 Cancer Cell 14, 226–237, September 9, 2008 ª2008 Elsevier Inusing a CpGenome DNA Modification Kit (Chemicon). PCR was performed us-
ing the primer sets 50-ATAATAGCGGTCGTTAGGGCGTCG-30 and 50-GCTTCT
ACTTTCCCGCTTCTCGCG-30 for methylated DNA and 50-ATAATAGTGGTTG
TTAGGGTGTTG-30 and 50-ACTTCTACTTTCCCACTTCTCACA-30 for unme-
thylated DNA as described previously (Homma et al., 2006). The PCR products
were subjected to sequencing.
Statistics
Statistical evaluation was performed by Student’s unpaired t test or Mann-
Whitney U test. Data are presented as mean ± SEM. p < 0.05 was considered
statistically significant.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, Sup-
plemental References, nine figures, and two tables and can be found with this
article online at http://www.cancercell.org/cgi/content/full/14/3/226/DC1/.
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